<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04961996</url>
  </required_header>
  <id_info>
    <org_study_id>GO42784</org_study_id>
    <secondary_id>2021-000129-28</secondary_id>
    <nct_id>NCT04961996</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)</brief_title>
  <official_title>A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III, global, randomized, open-label, multicenter, study evaluating the&#xD;
      efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's&#xD;
      choice in participants with medium- and high-risk Stage I-III histologically confirmed&#xD;
      estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative&#xD;
      early breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">November 21, 2033</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast Cancers</measure>
    <time_frame>From randomization to first occurrence of an IDFS event (up to 10 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization to death from any cause (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Disease-Free Survival (IDFS), Including Second Primary Non-Breast Cancers</measure>
    <time_frame>From randomization to first occurrence of an IDFS event (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>From randomization to first occurrence of a DFS event (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Recurrence-Free Interval (DRFI)</measure>
    <time_frame>From randomization to first occurrence of a DFRI event (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Recurrence-Free Interval (LRRFI)</measure>
    <time_frame>From randomization to first occurrence of a LRRFI event (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the EQ 5D-5L Index-Based Score at Specified Timepoints</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the EQ 5D-5L Visual Analogue Scale (VAS) Score at Specified Timepoints</measure>
    <time_frame>Baseline (Cycle 1) and Cycles 2, 3, 6, 9, 12, and every 3 cycles thereafter (1 cycle is 28 days) until end of treatment, then once every 6 months during post-treatment follow-up (up to 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)</measure>
    <time_frame>From start of treatment until 28 days after the final dose of study treatment (up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Giredestrant at Specified Timepoints</measure>
    <time_frame>Predose and 3 hours postdose on Day 1 of Cycles 1 and 2, and predose on Day 1 of Cycles 3 and 6 (1 cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4100</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Giredestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Endocrine Therapy of Physician's Choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Giredestrant</intervention_name>
    <description>Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).</description>
    <arm_group_label>Arm A: Giredestrant</arm_group_label>
    <other_name>GDC-9545</other_name>
    <other_name>RO7197597</other_name>
    <other_name>RG6171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine Therapy of Physician's Choice</intervention_name>
    <description>The endocrine therapy of physician's choice (TPC) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive TPC daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing TPC after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of TPC should be performed in accordance with the local prescribing information for the respective product.</description>
    <arm_group_label>Arm B: Endocrine Therapy of Physician's Choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH Agonist</intervention_name>
    <description>A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.</description>
    <arm_group_label>Arm A: Giredestrant</arm_group_label>
    <arm_group_label>Arm B: Endocrine Therapy of Physician's Choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented estrogen receptor (ER)-positive and HER2-negative breast tumor, as assessed&#xD;
             locally on a primary disease specimen&#xD;
&#xD;
          -  Participants who have multicentric (the presence of two of more tumor foci within&#xD;
             different quadrants of the same breast) and/or multifocal (the presence of two or more&#xD;
             tumor foci within a single quadrant of the breast) breast cancer are also eligible if&#xD;
             all examined tumors meet pathologic criteria for ER positivity and HER2 negativity&#xD;
&#xD;
          -  Participants must have undergone definitive surgery of the primary breast tumor(s).&#xD;
&#xD;
          -  Participants who received or will be receiving adjuvant chemotherapy must have&#xD;
             completed adjuvant chemotherapy prior to randomization. Participants may also have&#xD;
             received neoadjuvant chemotherapy. A washout period of at least 21 days is required&#xD;
             between last adjuvant chemotherapy dose and randomization.&#xD;
&#xD;
          -  Resolution of all acute toxic effects of prior anti-cancer therapy or surgical&#xD;
             procedures to NCI CTCAE v5.0 Grade 1 or better (except alopecia, Grade ≤2 peripheral&#xD;
             neuropathy, arthralgia or other toxicities not considered a safety risk for the&#xD;
             participant per the investigator's judgment)&#xD;
&#xD;
          -  Participants have received (neo)adjuvant chemotherapy and/or had surgery and had no&#xD;
             prior endocrine therapy are eligible, provided that they are enrolled within 12 months&#xD;
             following definitive breast cancer surgery&#xD;
&#xD;
          -  Participants who have confirmed availability of an untreated primary breast tumor&#xD;
             tissue specimen suitable for biomarker testing (i.e., representative archived&#xD;
             formalin-fixed, paraffin-embedded [FFPE] tissue block [preferred] or 15-20 slides&#xD;
             containing unstained, freshly cut, serial sections), with associated de-identified&#xD;
             pathology report is required. Although 15-20 slides are preferred, if only 10-14&#xD;
             slides are available, the individual may still be eligible for the study.&#xD;
&#xD;
          -  Participants with node-positive and node-negative disease are eligible provided they&#xD;
             meet additional risk criteria as defined in the protocol&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2&#xD;
&#xD;
          -  Able and willing to swallow, retain, and absorb oral medication&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             9 days after the final dose of giredestrant, or within the time period specified per&#xD;
             local prescribing guidelines after the final dose of the endocrine therapy of&#xD;
             physician's choice&#xD;
&#xD;
          -  Received treatment with investigational therapy within 28 days prior to initiation of&#xD;
             study treatment or is currently enrolled in any other type of medical research judged&#xD;
             by the sponsor not to be scientifically or medically compatible with this study&#xD;
&#xD;
          -  Receiving or planning to receive a CDK4/6i as adjuvant therapy&#xD;
&#xD;
          -  Active cardiac disease or history of cardiac dysfunction&#xD;
&#xD;
          -  Diagnosed with Stage IV breast cancer&#xD;
&#xD;
          -  A history of any prior (ipsilateral and/or contralateral) invasive breast cancer or&#xD;
             ductal carcinoma in situ (DCIS). Participants with a history of contralateral DCIS&#xD;
             treated by only local regional therapy at any time may be eligible.&#xD;
&#xD;
          -  A history of any other malignancy within 3 years prior to screening, except for&#xD;
             appropriately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, or&#xD;
             Stage I uterine cancer&#xD;
&#xD;
          -  Any prior endocrine treatment with selective ER downregulators or degraders or&#xD;
             aromatase inhibitors&#xD;
&#xD;
          -  Clinically significant liver disease consistent with Child-Pugh Class B or C,&#xD;
             including active hepatitis (e.g., hepatitis B virus [HBV] or hepatitis C virus [HCV]),&#xD;
             current alcohol abuse, cirrhosis, or positive test for viral hepatitis&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any of the study drugs or any of their excipients&#xD;
&#xD;
          -  Pre- and perimenopausal participants or male participants who have a known&#xD;
             hypersensitivity to LHRH agonists&#xD;
&#xD;
          -  A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism&#xD;
&#xD;
          -  A major surgical procedure unrelated to breast cancer within 28 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  A serious infection requiring oral or IV antibiotics within 14 days prior to screening&#xD;
             or other clinically significant infection (e.g., COVID-19) within 14 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the&#xD;
             investigator's judgment, precludes an individual's safe participation in and&#xD;
             completion of the study&#xD;
&#xD;
          -  Unable or unwilling to comply with the requirements of the protocol in the opinion of&#xD;
             the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GO42784 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CBCC Global Research Inc., at Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer and Blood Specialty Clinic</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology/Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Joseph Heritage Healthcare</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Torrance Memorial Physician Network/Cancer Care</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valley Breast Care and Women's Health Center</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stamford Hospital; Clincal Trials Office - 1st Fl - Bennett Cancer Cente</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System - Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital; Lurie Center for Autism</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology Research Unit</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Andrews Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital; Oncology/Haematology</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ballarat Oncology &amp; Haematology</name>
      <address>
        <city>Wendouree</city>
        <state>Victoria</state>
        <zip>3355</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sotiria Chest Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metropolitan General Hospital</name>
      <address>
        <city>Cholargos</city>
        <zip>155 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympion Clinic</name>
      <address>
        <city>Patras</city>
        <zip>264 43</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bon Secours Hospital; Oncology</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Centre</name>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Hokkaido</city>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riga East Clinical University Hospital Latvian Oncology Centre</name>
      <address>
        <city>Riga</city>
        <zip>LV-1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia; Servicio de Farmacia</name>
      <address>
        <city>Córdoba</city>
        <state>Cordoba</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <state>Sevilla</state>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Farmacia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

